VELA Investment Management LLC Takes $1.92 Million Position in Supernus Pharmaceuticals, Inc. $SUPN

VELA Investment Management LLC acquired a new stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) during the 3rd quarter, Holdings Channel reports. The fund acquired 40,251 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,924,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. USA Financial Formulas bought a new position in shares of Supernus Pharmaceuticals in the third quarter worth approximately $50,000. EverSource Wealth Advisors LLC purchased a new position in Supernus Pharmaceuticals in the 2nd quarter worth approximately $51,000. Raymond James Financial Inc. bought a new position in Supernus Pharmaceuticals in the 2nd quarter valued at approximately $55,000. Osaic Holdings Inc. boosted its stake in Supernus Pharmaceuticals by 211.5% during the 2nd quarter. Osaic Holdings Inc. now owns 1,956 shares of the specialty pharmaceutical company’s stock valued at $63,000 after purchasing an additional 1,328 shares during the last quarter. Finally, GAMMA Investing LLC increased its holdings in shares of Supernus Pharmaceuticals by 116.7% in the 2nd quarter. GAMMA Investing LLC now owns 2,861 shares of the specialty pharmaceutical company’s stock worth $90,000 after purchasing an additional 1,541 shares in the last quarter.

Analysts Set New Price Targets

SUPN has been the topic of a number of research analyst reports. TD Cowen upped their price target on Supernus Pharmaceuticals from $45.00 to $60.00 and gave the company a “buy” rating in a report on Thursday, October 23rd. Zacks Research lowered Supernus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, December 8th. Bank of America assumed coverage on shares of Supernus Pharmaceuticals in a report on Wednesday, October 29th. They set a “buy” rating and a $65.00 price target on the stock. Weiss Ratings reissued a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Monday, December 29th. Finally, Cantor Fitzgerald increased their price objective on shares of Supernus Pharmaceuticals from $46.00 to $63.00 and gave the company an “overweight” rating in a research report on Tuesday, September 30th. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $61.60.

Insiders Place Their Bets

In related news, SVP Frank Mottola sold 20,000 shares of the firm’s stock in a transaction on Friday, December 19th. The stock was sold at an average price of $50.41, for a total value of $1,008,200.00. Following the transaction, the senior vice president directly owned 15,496 shares of the company’s stock, valued at approximately $781,153.36. This trade represents a 56.34% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Padmanabh P. Bhatt sold 710 shares of the business’s stock in a transaction dated Thursday, December 18th. The shares were sold at an average price of $44.44, for a total value of $31,552.40. Following the sale, the vice president directly owned 14,508 shares of the company’s stock, valued at $644,735.52. This represents a 4.67% decrease in their position. The disclosure for this sale is available in the SEC filing. 8.80% of the stock is currently owned by company insiders.

Supernus Pharmaceuticals Stock Down 0.6%

Shares of NASDAQ:SUPN opened at $49.52 on Thursday. The stock has a market capitalization of $2.84 billion, a PE ratio of -145.64, a price-to-earnings-growth ratio of 0.48 and a beta of 0.67. The firm’s 50 day moving average price is $48.23 and its 200-day moving average price is $45.40. Supernus Pharmaceuticals, Inc. has a twelve month low of $29.16 and a twelve month high of $57.65.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its earnings results on Tuesday, November 4th. The specialty pharmaceutical company reported $0.46 EPS for the quarter, missing analysts’ consensus estimates of $0.82 by ($0.36). Supernus Pharmaceuticals had a negative net margin of 2.81% and a positive return on equity of 11.51%. The business had revenue of $170.00 million for the quarter, compared to analysts’ expectations of $175.82 million. During the same period in the prior year, the company posted $0.69 earnings per share. The firm’s quarterly revenue was up 9.3% on a year-over-year basis. Analysts expect that Supernus Pharmaceuticals, Inc. will post 2.38 earnings per share for the current fiscal year.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained?release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended?release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended?release capsules), approved for the treatment of attention?deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.